Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Morning Lantus [insulin glargine] v. intermediate-acting insulin 2x/day as basal insulin in a muliple daily inj. w/ Humalog [insulin lispro] in adolescents w/ type 1 diabetes mellitus: an active-controlled, open, randomized, gender-stratified, two-arm, parallel-group study

X
Trial Profile

Morning Lantus [insulin glargine] v. intermediate-acting insulin 2x/day as basal insulin in a muliple daily inj. w/ Humalog [insulin lispro] in adolescents w/ type 1 diabetes mellitus: an active-controlled, open, randomized, gender-stratified, two-arm, parallel-group study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin suspension isophane; Insulin zinc suspension
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Aventis Pharmaceuticals; Sanofi
  • Most Recent Events

    • 01 Mar 2009 Pharmacodynamic substudy published in Diabetes Care.
    • 05 Aug 2008 The expected completion date for this trial is now 1 Feb 2005.
    • 15 Sep 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top